Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Randomized, Double-blind Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label
Conditions
Interventions
Ficlatuzumab
Erlotinib
+1 more
Locations
47
United States
UCSF Fresno
Fresno, California, United States
Torrance Memorial Medical Center
Redondo Beach, California, United States
Boca Raton Regional Hospital Lynn Cancer Institute
Boca Raton, Florida, United States
University of Miami Sylvester Comprehensive Cancer Center Deerfield Beach
Deerfield Beach, Florida, United States
Kaiser Permanente Hawaii
Honolulu, Hawaii, United States
Cancer Center of Acadiana
Lafayette, Louisiana, United States
Start Date
November 1, 2014
Primary Completion Date
January 1, 2017
Completion Date
January 1, 2017
Last Updated
October 22, 2020
NCT06043817
NCT07144280
NCT07431827
NCT06758401
NCT06427941
NCT05910827
Lead Sponsor
AVEO Pharmaceuticals, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions